Figure 4.

Effects of oHSV Treatment on Tumor-Infiltrating Immune Cells

Mice were subcutaneously implanted with 5 × 10⁵ Pan02_HVEM cells and mock treated or treated with oHSV as described. Single cell suspension was prepared from tumor tissues on day 20 postinoculation. (A–N) Cells were then stained with fluorescence-conjugated antibodies and subjected to flow cytometry analysis for the contents of (A) CD45⁺ cells; (B) CD45⁺CD3⁺ cells; (C) CD45⁺CD4⁺ T cells; (D) CD45⁺CD8⁺ T cells; (E) CD4⁺CD25⁺Foxp3⁺Tregs; (F) the ratio of CD8⁺ T cells to Tregs; (G) IFN-γ⁺CD4⁺ cells; (H) GZMB⁺CD8⁺ cells; (I) PD-1⁺CD8⁺ cells; (J) macrophages (CD45⁺CD11b⁺F4/80⁺); (K) M1-like Mac (CD11b⁺F4/80⁺iNOS⁺); (L) M2-like Mac (CD11b⁺F4/80⁺CD206⁺); (M) M-MDSC (CD45⁺Ly6C⁺); and (N) G-MDSC (CD45⁺Ly6G⁺). The scatter graphs were plotted and presented as the percentage of an individual group of cells, as labeled on the vertical axis. Data were presented as mean values ± standard deviations, and statistics were analyzed using Student’s t test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.